Home
Scholarly Works
A phase 2, single agent study of Cl-1033...
Conference

A phase 2, single agent study of Cl-1033 administered at two doses in ovarian cancer patients who failed platinum therapy.

Authors

Campos SM; Seiden MV; Oza A; Plante M; Potkul R; Hamid O; Lenehan P; Kaldjian E; Jordan C; Hirte H

Volume

22

Pagination

pp. 462S-462S

Publisher

AMER SOC CLINICAL ONCOLOGY

Publication Date

July 15, 2004

Name of conference

40th Annual Meeting of the American-Society-of-Clinical-Oncology

Conference place

LA, New Orleans

Conference start date

June 5, 2004

Conference end date

June 8, 2004

Conference proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

14

ISSN

0732-183X

Labels

Fields of Research (FoR)

Contact the Experts team